Wave Life Sciences Ltd. financial data

Symbol
WVE on Nasdaq
Industry
Pharmaceutical Preparations
Location
7 Straits View, #12 00, Marina One East Tower, Singapore, Singapore
State of incorporation
Singapore
Fiscal year end
December 31
Former names
Wave Life Sciences Pte Ltd (to 11/2/2015)
Latest financial report
10-K - Q4 2024 - Mar 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 163 % +14.4%
Debt-to-equity 201 %
Return On Equity -104 % -139%
Return On Assets -33.6 % -42%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 153M shares +25.5%
Common Stock, Shares, Outstanding 153M shares +28.4%
Entity Public Float 489M USD +88.9%
Common Stock, Value, Issued 1.18B USD +25.6%
Weighted Average Number of Shares Outstanding, Basic 138M shares +30.3%
Weighted Average Number of Shares Outstanding, Diluted 138M shares +30.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 111M USD +202%
Research and Development Expense 160M USD +22.8%
General and Administrative Expense 59M USD +15.1%
Operating Income (Loss) -110M USD -62.4%
Nonoperating Income (Expense) 13.4M USD +36.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -97M USD -66.7%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -97M USD -68.7%
Earnings Per Share, Basic -0.7 USD/shares -29.6%
Earnings Per Share, Diluted -0.7 USD/shares -29.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 302M USD +50.8%
Accounts Receivable, after Allowance for Credit Loss, Current 1.42M USD -93.3%
Other Assets, Current 7.35M USD +82.7%
Assets, Current 320M USD +36.1%
Property, Plant and Equipment, Net 10.1M USD -22.6%
Operating Lease, Right-of-Use Asset 17.9M USD -21.1%
Other Assets, Noncurrent 55K USD -64.7%
Assets 352M USD +28.1%
Accounts Payable, Current 16.3M USD +26.7%
Employee-related Liabilities, Current 15.4M USD +9.19%
Accrued Liabilities, Current 4.55M USD +157%
Contract with Customer, Liability, Current 66M USD -56%
Liabilities, Current 111M USD -40.5%
Contract with Customer, Liability, Noncurrent 6.1M USD -60.9%
Operating Lease, Liability, Noncurrent 17.8M USD -30.1%
Other Liabilities, Noncurrent 190K USD
Liabilities 135M USD -40.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -262K USD -111%
Retained Earnings (Accumulated Deficit) -1.12B USD -9.47%
Stockholders' Equity Attributable to Parent 210M USD +429%
Liabilities and Equity 352M USD +28.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.4M USD -139%
Net Cash Provided by (Used in) Financing Activities 14.5M USD -58.6%
Net Cash Provided by (Used in) Investing Activities -417K USD +14.7%
Common Stock, Shares, Issued 153M shares +28.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -19.4M USD -116%
Deferred Tax Assets, Valuation Allowance 272M USD +10.2%
Deferred Tax Assets, Gross 277M USD +9.31%
Operating Lease, Liability 25.4M USD -20.9%
Depreciation 1.04M USD -27.3%
Payments to Acquire Property, Plant, and Equipment 417K USD -14.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -97.1M USD -68.6%
Lessee, Operating Lease, Liability, to be Paid 29M USD -24.3%
Property, Plant and Equipment, Gross 56.5M USD +1.19%
Operating Lease, Liability, Current 7.64M USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.58M USD -0.07%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.59M USD +3.01%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.64M USD -41.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.99M USD -6.23%
Deferred Tax Assets, Operating Loss Carryforwards 178M USD +2.95%
Unrecognized Tax Benefits 20.8M USD +31.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 886K USD -90.1%
Additional Paid in Capital 156M USD +21.1%
Deferred Tax Assets, Net of Valuation Allowance 4.67M USD -24.6%
Share-based Payment Arrangement, Expense 2.88M USD +4.76%